All In Biotech

BLA 103471 · Bayer Healthcare Pharms

Betaseron

Interferon Beta-1b · Subcutaneous

NovelAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: May 9, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1993

Jul 23, 1993

Approved uses

5

Original approval plus efficacy supplements

Registered trials

54

12 Phase 3, 0 recruiting

FAERS reports

19,082

10,670 serious, 1,337 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 3, 2026.

BETASERON is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. BETASERON is an interferon beta indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )

Mechanism: The mechanism of action of BETASERON (interferon beta-1b) in patients with multiple sclerosis is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 26, 2017 Supplement 5189 · Efficacy LetterReview
  • Sep 25, 2015 Supplement 5186 · Efficacy LabelReviewLetter
  • Oct 20, 2006 Supplement 5081 · Efficacy
  • Mar 14, 2003 Supplement 1039 · Efficacy · priority review OrphanLetterLabelReview
  • Jul 23, 1993 Original approval · Type 1 - New Molecular Entity · priority review Review
1 products under this application
  • BETASERON · INTERFERON BETA-1B 0.3 MG · VIAL, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Interferon Beta-1b" as an intervention, any sponsor and status, largest first.

All 54 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • influenza like illness1,404
  • multiple sclerosis relapse1,346
  • injection site pain1,198
  • fatigue1,197
  • multiple sclerosis1,166
  • injection site erythema978
  • drug ineffective970
  • pain855
  • headache844
  • injection site reaction842
  • fall819
  • depression815

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004405
2005535
2006803
20071,200
2008368
2009502
2010747
20111,162
20121,785
20131,656
20141,564
20151,381
20161,393
20171,291
20181,158
2019986
2020583
2021400
2022352
2023322
2024197
2025176
2026115

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Betaseron (Interferon Beta-1b)

2024 spending

$92.2M

Beneficiaries

1,042

9,136 claims

Per beneficiary

$88,521

$689.48 per unit

View as table
YearSpending
2020$163,581,521
2021$130,156,657
2022$118,527,291
2023$103,287,436
2024$92,238,675

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 223 on PubMed

Sponsor: Bayer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.